An historic shift towards treating cancer based on a tumor’s genetics rather than its site of origin is underway. Genomically-targeted drugs, properly developed, have an inherent advantage over drugs that are not. But the success of any one will depend on good strategic planning, done early. Read about three key considerations for crafting a successful genomic biomarker strategy.
Other content in this Stream
Building oncology trials for those who need them most.
Three strategies that apply multidisciplinary solutions earlier in the development process to reduce failures and accelerate CNS drug development.
Read this article to find out more about orphan diseases.